Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106250846> ?p ?o ?g. }
- W2106250846 endingPage "869" @default.
- W2106250846 startingPage "860" @default.
- W2106250846 abstract "ObjectiveCD229, a cell-surface molecule being involved in cell adhesion, is overexpressed in B-CLL cells. In this study we wanted to explore whether CD229 might function as B-CLL-specific tumor-associated antigen (TAA).Patients and MethodsAutologous, CD229-specific HLA-A2-restricted T cells were identified using IFN-γ-ELISPOT assays and HLA-A2/dimer-peptide staining after 4 weeks of in vitro culture.ResultsWe were able to expand autologous T cells from 9/11 B-CLL patients using native B-CLL cells as antigen presenting cells (APCs) in 5 cases, whereas for 4 samples an autologous T-cell response could only be evoked by use of CD40L-stimulated B-CLL cells as APCs. The number of CD8+ T cells could be expanded during 4 weeks of in vitro culture with native or CD40L-activated B-CLL cells while the amount of specific T cells recognizing CD229 peptides bound to HLA-A2 dimers increased on average 12-fold (native CLL) and 13-fold (CD40L-activated CLL), respectively. Using IFN-γ-ELISPOT assays we could demonstrate that the expanded T cells were able to secrete IFN-γ upon recognition of the antigen. These T cells not only recognized HLA-A0201-binding CD229-derived peptides presented by T2 cells, but also CD229-overexpressing autologous B-CLL cells in an MHC-I-restricted manner.ConclusionIn summary, CD229 was shown to be naturally processed and presented as TAA in primary B-CLL cells, enabling the expansion of autologous tumor-specific T cells. CD229, a cell-surface molecule being involved in cell adhesion, is overexpressed in B-CLL cells. In this study we wanted to explore whether CD229 might function as B-CLL-specific tumor-associated antigen (TAA). Autologous, CD229-specific HLA-A2-restricted T cells were identified using IFN-γ-ELISPOT assays and HLA-A2/dimer-peptide staining after 4 weeks of in vitro culture. We were able to expand autologous T cells from 9/11 B-CLL patients using native B-CLL cells as antigen presenting cells (APCs) in 5 cases, whereas for 4 samples an autologous T-cell response could only be evoked by use of CD40L-stimulated B-CLL cells as APCs. The number of CD8+ T cells could be expanded during 4 weeks of in vitro culture with native or CD40L-activated B-CLL cells while the amount of specific T cells recognizing CD229 peptides bound to HLA-A2 dimers increased on average 12-fold (native CLL) and 13-fold (CD40L-activated CLL), respectively. Using IFN-γ-ELISPOT assays we could demonstrate that the expanded T cells were able to secrete IFN-γ upon recognition of the antigen. These T cells not only recognized HLA-A0201-binding CD229-derived peptides presented by T2 cells, but also CD229-overexpressing autologous B-CLL cells in an MHC-I-restricted manner. In summary, CD229 was shown to be naturally processed and presented as TAA in primary B-CLL cells, enabling the expansion of autologous tumor-specific T cells." @default.
- W2106250846 created "2016-06-24" @default.
- W2106250846 creator A5018804552 @default.
- W2106250846 creator A5025914217 @default.
- W2106250846 creator A5039854315 @default.
- W2106250846 creator A5069297179 @default.
- W2106250846 creator A5076077834 @default.
- W2106250846 date "2006-07-01" @default.
- W2106250846 modified "2023-10-17" @default.
- W2106250846 title "Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells" @default.
- W2106250846 cites W132916333 @default.
- W2106250846 cites W1544597713 @default.
- W2106250846 cites W1563658297 @default.
- W2106250846 cites W1577612079 @default.
- W2106250846 cites W1970695164 @default.
- W2106250846 cites W1975489352 @default.
- W2106250846 cites W1984655584 @default.
- W2106250846 cites W1995541635 @default.
- W2106250846 cites W2007362831 @default.
- W2106250846 cites W2021964934 @default.
- W2106250846 cites W2025938134 @default.
- W2106250846 cites W2028475115 @default.
- W2106250846 cites W2031144213 @default.
- W2106250846 cites W2042761559 @default.
- W2106250846 cites W2043171078 @default.
- W2106250846 cites W2048967247 @default.
- W2106250846 cites W2051708207 @default.
- W2106250846 cites W2061181260 @default.
- W2106250846 cites W2067353129 @default.
- W2106250846 cites W2078161165 @default.
- W2106250846 cites W2079542677 @default.
- W2106250846 cites W2088849552 @default.
- W2106250846 cites W2116293732 @default.
- W2106250846 cites W2124010557 @default.
- W2106250846 cites W2132861582 @default.
- W2106250846 cites W2134001636 @default.
- W2106250846 cites W2144935474 @default.
- W2106250846 cites W2145928191 @default.
- W2106250846 cites W2149940155 @default.
- W2106250846 cites W2164746699 @default.
- W2106250846 cites W60865865 @default.
- W2106250846 doi "https://doi.org/10.1016/j.exphem.2006.04.010" @default.
- W2106250846 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16797413" @default.
- W2106250846 hasPublicationYear "2006" @default.
- W2106250846 type Work @default.
- W2106250846 sameAs 2106250846 @default.
- W2106250846 citedByCount "17" @default.
- W2106250846 countsByYear W21062508462012 @default.
- W2106250846 countsByYear W21062508462014 @default.
- W2106250846 countsByYear W21062508462015 @default.
- W2106250846 countsByYear W21062508462016 @default.
- W2106250846 countsByYear W21062508462017 @default.
- W2106250846 countsByYear W21062508462018 @default.
- W2106250846 countsByYear W21062508462019 @default.
- W2106250846 countsByYear W21062508462020 @default.
- W2106250846 crossrefType "journal-article" @default.
- W2106250846 hasAuthorship W2106250846A5018804552 @default.
- W2106250846 hasAuthorship W2106250846A5025914217 @default.
- W2106250846 hasAuthorship W2106250846A5039854315 @default.
- W2106250846 hasAuthorship W2106250846A5069297179 @default.
- W2106250846 hasAuthorship W2106250846A5076077834 @default.
- W2106250846 hasConcept C129374314 @default.
- W2106250846 hasConcept C147483822 @default.
- W2106250846 hasConcept C153911025 @default.
- W2106250846 hasConcept C154317977 @default.
- W2106250846 hasConcept C167672396 @default.
- W2106250846 hasConcept C185592680 @default.
- W2106250846 hasConcept C202751555 @default.
- W2106250846 hasConcept C203014093 @default.
- W2106250846 hasConcept C2776090121 @default.
- W2106250846 hasConcept C2779053233 @default.
- W2106250846 hasConcept C39347974 @default.
- W2106250846 hasConcept C502942594 @default.
- W2106250846 hasConcept C55493867 @default.
- W2106250846 hasConcept C67662055 @default.
- W2106250846 hasConcept C86803240 @default.
- W2106250846 hasConcept C8891405 @default.
- W2106250846 hasConceptScore W2106250846C129374314 @default.
- W2106250846 hasConceptScore W2106250846C147483822 @default.
- W2106250846 hasConceptScore W2106250846C153911025 @default.
- W2106250846 hasConceptScore W2106250846C154317977 @default.
- W2106250846 hasConceptScore W2106250846C167672396 @default.
- W2106250846 hasConceptScore W2106250846C185592680 @default.
- W2106250846 hasConceptScore W2106250846C202751555 @default.
- W2106250846 hasConceptScore W2106250846C203014093 @default.
- W2106250846 hasConceptScore W2106250846C2776090121 @default.
- W2106250846 hasConceptScore W2106250846C2779053233 @default.
- W2106250846 hasConceptScore W2106250846C39347974 @default.
- W2106250846 hasConceptScore W2106250846C502942594 @default.
- W2106250846 hasConceptScore W2106250846C55493867 @default.
- W2106250846 hasConceptScore W2106250846C67662055 @default.
- W2106250846 hasConceptScore W2106250846C86803240 @default.
- W2106250846 hasConceptScore W2106250846C8891405 @default.
- W2106250846 hasIssue "7" @default.
- W2106250846 hasLocation W21062508461 @default.
- W2106250846 hasLocation W21062508462 @default.
- W2106250846 hasOpenAccess W2106250846 @default.
- W2106250846 hasPrimaryLocation W21062508461 @default.